As it cuts costs and pipeline, Bristol Myers hands back a cancer drug to Schrödinger
Bristol Myers Squibb will give back a preclinical cancer drug to Schrödinger, returning the SOS1 inhibitor that was part of a 2020 deal between the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
